CellPro's Ceprate system cleared by the FDA
This article was originally published in Clinica
Executive Summary
CellPro's Ceprate stem cell concentration system for purification of stem cells for bone marrow transplantation has been approved by the FDA for marketing in the US. Clinical trials of the system for autologous bone marrow transplantation for patients with breast cancer showed that it reduced infusional toxicity and side effects while maintaining an acceptable time to engraftment.